Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00006381 · ClinicalTrials.gov registry record · Phase 2
Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer
A Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
- Completed
- Registry status
- Phase 2
- Development phase
NCT00006381: Completed Phase 2 study, sponsored by Memorial Sloan Kettering Cancer Center.
NCT00006381 is a Phase 2 study that has completed, run by Memorial Sloan Kettering Cancer Center. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00006381, a Phase 2 study, has completed, sponsored by Memorial Sloan Kettering Cancer Center.
- COMPLETED
- Registry status
- Phase 2
- Development phase
Study Summary
RATIONALE: Celecoxib may be effective in preventing the further development of cancer. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining trastuzumab with celecoxib may kill more tumor cells. PURPOSE: Phase II trial to study the effectiveness of combining celecoxib and trastuzumab in treating women who have metastatic breast cancer that has not responded to previous trastuzumab.
Interventions
- BIOLOGICAL trastuzumab
- DRUG celecoxib
Trial Details
| Field | Value |
|---|---|
| Start Date | 2000-06 |
| Est. Completion | 2004-02 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00006381
The ClinicalTrials.gov registry entry for NCT00006381 describes a study currently listed as completed, categorized as Phase 2. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Memorial Sloan Kettering Cancer Center, which has 1,884 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which trastuzumab is the first listed.
NCT00006381 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00006381 about?
NCT00006381 is a clinical study titled "Celecoxib and Trastuzumab in Treating Women With Metastatic Breast Cancer". RATIONALE: Celecoxib may be effective in preventing the further development of cancer. Monoclonal antibodies such as trastuzumab can locate tumor cells and either kill them or deliver tumor-killing substances to them without harming normal cells. Combining trastuzumab with celecoxib may kill more tu...
What is the current status of trial NCT00006381?
This trial is currently completed. It is a Phase 2 study. The study started on 2000-06. Estimated completion is 2004-02.
What interventions are being tested in trial NCT00006381?
The interventions under investigation include: trastuzumab (BIOLOGICAL), celecoxib (DRUG).
Who is sponsoring clinical trial NCT00006381?
This trial is sponsored by Memorial Sloan Kettering Cancer Center, which has 1,884 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.